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1. Introduction 
Obscure gastrointestinal bleeding (OGIB) is defined as occult or overt bleeding of unknown 
origin that persists or recurs despite negative primary radiological and endoscopic studies. 
It can be classified into two different clinical forms: obscure-overt OGIB, defined as visible 
passage of blood (ie, melena or hematochezia) and obscure-occult OGIB, manifested by iron-
deficiency anemia or positive fecal occult blood test without other evidence of bleeding.1  
Since the source of bleeding is not readily identifiable by upper GI endoscopy and 
colonoscopy, OGIB is therefore, by definition, recurrent. Approximately, 5% of GI bleeding 
occurs between the ligament of Treitz and the ileocecal valve. Angiodysplasias of the small 
bowel account for 30% to 40% of OGIB and are the most common source of bleeding in 
patients over 60 years.1,2 They can be found as a primary disease or a gastrointestinal 
manifestation of systemic diseases such as hereditary haemorrhagic telangiectasia (HHT), 
von Willebrand (vW) disease, cardiac valvular disease, radiation enteritis, end-stage renal 
disease, portal hypertension, connective tissue diseases or vasculitis. Other causes include 
non-steroidal anti-inflammatory drugs enteropathy, inflammatory bowel disease, small 
bowel tumors (ie, leiomyomas, carcinoid, lymphomas, adenocarcinomas), Meckel´s 
diverticulum or Dieulafoy´s lesion. 
Over the last decade, the diagnostic yield and therapeutic capabilities of small bowel 
endoscopy have dramatically changed with the development of video capsule endoscopy 
and deep enteroscopy systems (single balloon, double balloon or spiral). Nonetheless, the 
diagnostic yield is 75% at best combining both techniques, so a quarter of patients lack a 
diagnosis of the source of bleeding despite exhaustive evaluation and may be at high risk of 
rebleeding.1 Additionally, a variable percentage of patients with a diagnosis may not 
respond to endoscopic therapy or may not be tributary to aggressive endoscopic or surgical 
management due to severe comorbidities or diffuse distribution of lesions throughout the 
GI tract. In this particular subset of patients, medical therapy is commonly required to stop, 
or at least, ameliorate bleeding, which usually leads to high transfusional requirements, 
exacerbations of medical conditions and subsequent hospital admissions. Indications for 
medical therapy in OGIB, as approved in the latest American Gastroenterology Association 
technical review, are listed in Table 1.2 
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1. Patients who are not candidates or do not respond to 
endoscopic, surgical or interventional radiological therapy. 
 
2. Diffuse vascular lesions in the small bowel or extended to 
upper or lower segments. 
 
3. Relative unaccesible location of lesions for endoscopy. 
 
4. Unknown source of bleeding. 
Table 1. Indications for pharmacological therapy in OGIB 
The aim of this chapter is to give an overview of current scientific evidence supporting the 
use of pharmacological therapy in these, often difficult to treat, OGIB patients. The standard 
diagnostic and therapeutic approach involving endoscopic and radiological techniques, the 
management of concomitant antiplatelet and anticoagulant drugs and the supportive care of 
anemia in OGIB patients, are described elsewhere. Up to date, data regarding pharmacological 
agents for OGIB are scarce and exclusively based on case reports and small uncontrolled 
studies. The available evidence suggests a potential role for pharmacological therapy as an 
adjunctive measure in patients with either multiple comorbidities or in whom lesions are 
inaccessible or refractory to endoscopic therapy. However, their clinical utility remains to be 
proven in randomized controlled trials. Similarly, the appropriate dose and schedule 
required for long-term therapy are also unknown. The different pharmacological agents 
used for OGIB reported in the literature are listed in Table 2. 
 
Hormonal therapy 
Somatostatin analogues 
Octreotide 
Long acting release (LAR) octreotide 
Lanreotide 
 
Antiangiogenic drugs 
Thalidomide 
Lenalidomide 
Bevacizumab 
 
Miscellaneous 
Antifibrinolytics (aminocaproic acid, tranexamic acid) 
Danazol 
Desmopressin 
Recombinant activated factor VII 
Tamoxifen 
Non selective beta-blockers 
Table 2. Pharmacological agents used in OGIB  
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Depending on the type of bleeding 
Life-threatening: vasoactive medication, rFVIIa 
Depending on the source of bleeding 
Angiodysplasias: long-acting somatostatin analogues, 
antiangiogenic drugs (thalidomide, lenalidomide) 
 
Hereditary hemorrhagic telangiectasia: antifibrinolytics, 
tamoxifen, antiangiogenic drugs (thalidomide, bevacizumab) 
 
Portal hypertension: beta-blockers 
 
von Willebrand disease: desmopressin, vW factor, antifibrinolytics 
Table 3. Suggested therapeutic algoritham for pharmacological therapy in OGIB 
2. Hormonal therapy 
Estrogen-progesterone combination was proposed for OGIB because of preliminary reports 
of improvement of epistaxis in patients with HHT during pregnancy and further relapse in 
the puerperium.3 Its effect, which is not immediate, seems to be estrogen dose-dependent 
and acts by enhancing microvascular circulation, coagulation, and vascular endothelial 
integrity. The most common combination schedule has been ethynil estradiol 0.01-0.05 mg 
and noresthisterone 1-3 mg.4 This therapy should be used over six-month periods with 
pauses to reduce the incidence of adverse effects, mostly due to the estrogen component 
(vascular thrombosis, gynecomastia and loss of libido in men, breast tenderness and vaginal 
bleeding in women). However, the two largest placebo-controlled studies addressing the 
impact of hormonal therapy on GI bleeding from angiodysplasias failed to demonstrate any 
significant benefit. In the first study, patients with out-of-reach bleeding small-bowel 
angiodysplasias were treated using high-dose estrogens, estrogen-progesterone or placebo, 
but no statistical improvement of transfusion requirements was observed amongst the 
groups.5 Additionally, in the second study, the authors failed to identify any significant 
effect of hormonal therapy compared to placebo in 72 non-cirrhotic patients bleeding from 
documented angiodysplasia6. This latter study, however, has setbacks such as the use of low 
doses of ethynil estradiol and the exclusion of patients with vascular ectasia associated to 
cirrhosis and HHT. Overall, the effectiveness of hormonal therapy remains unclear and both 
negative controlled trial results and serious and frequent side effects strongly limit its use in 
OGIB. Recent reports on the effectiveness of other agents with an improved safety profile 
displace hormonal therapy as first-line therapeutic option for OGIB. 
3. Somatostatin analogues 
In 1993, octreotide was first reported for the treatment of bleeding small bowel 
angiodysplasias, in a small series of three patients successfully treated for 10 to 40 months.7 
The rationale for the use of somatostatin analogues is based on its effects on splanchnic 
circulation, as they induce a marked reduction of portal and mesenteric blood flow 
mediated through inhibition of vasodilator peptides. Additionally, experimental studies 
have shown that octreotide has antiangiogenic effects, by downregulation of vascular 
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endothelial growth factor (VEGF).8 In fact, a study reported endoscopic resolution of 
angiodysplastic lesions after treatment with octreotide, albeit the effect was not quantified.9 
Interestingly, a more recent study showed that a 3-month-treatment of long-acting release 
(LAR) octreotide 20 mg once a month in cirrhotic patients decreased significantly both the 
hepatic venous pressure gradient and VEGF in hepatic venous blood.10 Other potential 
mechanisms of action of somatostatin analogues in OGIB, although more controversial, are 
by increasing vascular resistance and improving platelet aggregation. 
Octreotide is, by far, the most studied somatostatin analogue in OGIB. However, recent 
studies are focusing on long-acting intramuscular (LAR octreotide) or subcutaneous 
(lanreotide) formulations, which have the great advantage of a once monthly administration. 
A recent meta-analysis, which included three prospective studies, aimed at evaluating the 
effectiveness of conventional and depot somatostatin analogues for bleeding vascular 
malformations, showed an average clinical response rate of 76%.11 Despite the small sample 
size of the studies included and the heterogeneity in the dose and molecular forms of the 
medication, these results are encouraging and a trial of somatostatin analogues is 
warranted, especially in patients in whom endoscopic therapy has failed, with unaccessible 
lesions or unknown source of bleeding. Its good safety profile, when compared with other 
pharmacological agents such as hormonal therapy or thalidomide, is another meaningful 
advantage. Nonetheless, randomized controlled trials are needed to confirm this data. 
3.1 Octreotide 
Octreotide can be administered intravenously (50 µg per hour) or subcutaneously (50-100 µg 
b.i.d or t.i.d). Its main disadvantage for long-term therapy is the need of parenteral 
administration several times a day, owing to its short half-life (90-120 minutes). Octreotide 
has been reported successful in stopping GI bleeding from angiodysplasia in multiple case 
reports and small series, both in acute and chronic bleeding.  
To date, the most solid evidence is obtained in two prospective cohort studies, the latter 
comparing the results to historical controls. The former included 17 patients, (of whom 6 
were cirrhotic), with chronic bleeding from angiodysplasias. 7 patients had isolated 
angiodysplasias, whereas other 7 had diffuse lesions in upper and lower segments of the GI 
tract and 3 watermelon stomach.9 Octreotide was given subcutaneously (100 µg t.i.d) for 6 
months. More than half of the patients (10/17) achieved complete remission without further 
iron or transfusion requirements, whereas a transient improvement was observed in another 
4 patients. Of note, octreotide lead subjectively to disappearance or reduction of the number, 
size and colour of the vascular malformations on follow-up endoscopy. The second study 
included 32 patients with acute or chronic bleeding due to GI angiodysplasias, which were 
treated with octreotide 50 µg b.i.d for a 1-2 yr period.12 Cirrhotic patients were excluded. 
Treatment failure (rebleeding or iron deficiency anemia during follow-up) was significantly 
higher in the controls cohort (48%) in comparison with the octreotide cohort (23%). A 
significant decrease in iron requirements, but not in hemoglobin or transfusion requirements, 
was also observed in the octreotide arm. Adverse effects in both studies were uncommon 
and mild, including diarrhea, constipation, hyperglycemia or gallbladder stones. 
3.2 Long-acting release (LAR) octreotide 
Several case reports and small series have recently revealed the efficacy of a depot 
formulation of octreotide (LAR octreotide) for severe OGIB, either of unknown origin or 
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related to diffuse small bowel angiodysplasias.13-18 LAR octreotide is administered 
intramuscularly monthly, which makes it an attractive and comfortable therapy on an 
outpatient basis. 
Two small prospective uncontrolled series have been published using LAR octreotide. In the 
first study, 13 patients with chronic GI bleeding due to angiodysplasias were treated with 
octreotide LAR 10 mg per month and followed for at least 1 year.19 Nine out of the thirteen 
patients (69%) did not require further blood or iron supplementation, and partial 
improvement was also observed in another patient. The second study addressed the 
response to octreotide LAR 20 mg per month in a cohort of 11 elderly patients with multiple 
comorbidities and severe OGIB, mostly related to small-bowel diffuse angiodysplasia 
(72%).20 Median follow-up was 15 months (5-48). Only 2 out of 11 patients (18%) remained 
free of transfusions. However, a significant decrease in the need of red cell packets (14 (9-49) 
vs 4 (0-9), p 0.002) and in hospital stay due to GI bleeding (27 days (10-99) vs 7 days (0-23),  
p<0.001) during the first year of treatment was observed. These less promising results were 
perhaps due to a higher proportion of patients on anticoagulation or antiplatelet therapy, 
which was not withdrawn at study inclusion. Furthermore, the patients included in this 
study had more severe GI bleeding as shown by higher transfusional requirements. 
The main disadvantage of this drug formulation is its high cost, ranging from 785 euros 
(10mg) to 1300 euros (30 mg) monthly. However, it may be cost-effective in very specific 
difficult to treat patients, only tributary to conservative management, with higher 
transfusional requirements and repeat admissions.  
3.3 Lanreotide 
The main advantage of lanreotide over LAR octreotide is its subcutaneous administration, 
avoiding painful intramuscular injections and their inherent risk for complication in 
anticoagulated or cirrhotic patients. Up to date, there is only a case report on the successful 
use of lanreotide in a patient with severe OGIB due to universal portal hypertension 
stigmata in stomach, small bowel and colon.21 After a successful response to octreotide at a 
dose of 100 µg twice a day, the patient was given lanreotide, administered at dose of 60 mg, 
subcutaneously, on a monthly basis. This drug achieved complete remission of bleeding 
during 15 months of follow-up.  
4. Antiangiogenic drugs 
4.1 Thalidomide 
Thalidomide is a drug with powerful immunomodulatory, anti-inflammatory and 
antiangiogenic effects, banned in the 1960s because of its teragenocity. However, it has been 
recently reintroduced for the treatment of leprosy, multiple myeloma and a variety of 
tumors. Over the last decade, thalidomide has gained interest as a therapeutic tool for OGIB. 
The rationale for its use in bleeding GI angiodysplasias is based on the inhibition of VEGF-
dependent angiogenesis. It is administered orally at a variable dose of 100-300 mg per day, 
usually during a 3-month course due to adverse effects. 
Thalidomide has been reported to be effective in controlling refractory severe bleeding from 
small bowel angiodysplasia, bleeding portal hypertensive gastropathy and enteropathy, 
radiation-induced proctitis and Crohn´s disease.22-29 Thalidomide, at a dose of 100 mg per 
day for three months, controlled OGIB in a case series of 3 patients with chronic bleeding 
from small-bowel angiodysplasia evidenced by capsule endoscopy.30 Repeat capsule 
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endoscopy after therapy revealed a substantial reduction in lesion number, size and colour 
intensity. Of note, the response was sustained for a median of 34 months despite 
discontinuation of the drug. Due to its antiangiogenic property, thalidomide may not only 
lead to cessation of bleeding but also to prevention of further angiodysplasia formation. 
More recently, two small prospective series, involving 3 and 7 patients, respectively, have 
confirmed the utility of thalidomide for bleeding small-bowel angiodysplasia.31,32 However, 
a high rate of discontinuation was observed in these series (1/3 and 4/7, respectively), 
owing to intolerable side effects (fatigue, peripheral neuropathy, dizziness, urticarial rash). 
The main drawback of thalidomide is it frequent side effects, although these are mostly 
minor (fatigue, somnolence, constipation, dizziness, peripheral neuropathy). Nonetheless, 
fatal complications such as acute liver failure have been reported.33 In addition, the risk of 
thromboembolic events associated with thalidomide should be considered in OGIB patients. 
Overall, thalidomide is an effective drug for refractory bleeding GI angiodysplasia. Taking 
into account its numerous side effects, it seems cautious to save thalidomide for OGIB 
refractory to both endoscopic therapy and a trial of somatostatin analogues, albeit a head-to-
head comparison is required to validate this algorithm.  
4.2 Lenalidomide  
Lenalidomide is an antiangiogenic drug commonly used for multiple myeloma. It has two 
mayor advantages over thalidomide: a more powerful antiangiogenic effect and a lower 
toxicity profile. Its use in the context of life-threatening bleeding due to gastrointestinal 
angiodysplasia in a patient suffering from HHT, in whom thalidomide was effective but had 
to be stopped because of severe neuropathy has been recently reported34. Lenalidomide 
successfully controlled bleeding and the patient remained free of either gastrointestinal 
bleeding or drug symptoms. However, although lenalidomide is more effective and better 
tolerated than thalidomide, further studies are warranted to evaluate its role in refractory 
OGIB. On the other hand, lenalidomide is 10 times more expensive than thalidomide and 
dosing should be carefully titrated owing to severe bone marrow suppression, much higher 
than that described for thalidomide. 
4.3 Bevacizumab 
Recently, a growing number of reports on the use of VEGF antagonist bevacizumab in HHT 
have lead to outstanding improvement in GI bleeding episodes, reductions in cardiac output 
and liver size, even obviating the need for liver transplantation in a single patient.35,36 This 
benefit has been also proven for recurrent epistaxis, administering bevacizumab 
intravenously, injected locally or sprayed topically to the nasal mucosa.37,38 
5. Miscellaneous drugs 
5.1 Antifibrinolytics 
Aminocaproic acid is a powerful inhibitor of the fibrinolytic system that blocks conversion 
of plasminogen to plasmin when used at low doses. There is only one isolated report in 
which it was effective in the management of epistaxis from arteriovenous malformations in 
two patients with HHT at a dose of 1.5 g twice a day, although it was not clear whether 
concomitant gastrointestinal bleeding was present.39  
Tranexamic acid is a synthetic lysine analog that inhibits the conversion of plasmin to 
fibrinogen, with less antifibrinolytic power than aminocaproic acid. Tranexamic acid has 
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been proven useful for chronic bleeding from angiodysplasias in patients with end-stage 
renal failure and bleeding gastric antral vascular ectasia in cirrhosis.40-42 A systematic review 
on the use of tranexamic acid for upper GI bleeding was recently published.43 Although it 
seemed to reduce overall mortality, there were no significant differences regarding bleeding, 
surgery or transfusion requirements. Of note, tranexamic acid did not increase 
thromboembolic risk. Therefore, the current evidence does not support routine use of 
tranexamic acid in clinical practice. The main risk derived from the use of antifibrinolytics is 
thrombosis, so thrombophilia should be ruled out before prescribing them. Adverse events 
associated to ACA and tranexamic acid may be frequent, and the use of these drugs is not 
supported by randomized controlled trials, which makes antifibrinolytics a last option for 
OGIH. 
5.2 Danazol 
Danazol is an anti-gonadotropin drug with weak androgenic activity that blocks pituitary 
secretion of FSH and LH, leading to ectopic and normal endometrial tissue atrophy. It has 
been widely used for endometriosis and uterine bleeding disorders. Anecdotal reports 
suggest a partial improvement with danazol in patients with gastrointestinal bleeding and 
HHT,44-46 although cosmetic stigmata (acne, hair loss, mild hirsutism) and uncommon but 
severe adverse effects (intracranial hypertension, peliosis hepatitis, thrombosis, seizures) 
leave danazol to a secondary role in OGIH, when other therapies have failed. 
5.3 Desmopressin 
Desmopressin is a synthetic analog of the antidiuretic hormone vasopressin that lacks 
vasopressor activity. It increases vW factor and factor VIII levels, and also enhances 
hemostasis in patients with defective platelet function. It is indicated as a hemostatic 
therapy for patients with hemophilia A and von Willebrand’s disease, and can be 
administered intravenously, subcutaneously, or by intranasal spray. An isolated report 
showed a benefit of intravenous desmopressin for life-threatening gastrointestinal bleeding 
in a patient with HHT and vW factor deficiency, allowing elective colectomy and bleeding 
resolution47. 
5.4 Recombinant activated factor VIIa 
Recombinant activated human factor VII (rFVIIa) is a drug that strongly promotes 
hemostasis, and is currently indicated for hemophiliac A and B patients with antibody 
inhibitors to coagulation factors VIII or IX, congenital deficiency of factor VII, and 
Glanzmann’s thromboasthenia. This drug has been used anecdoctically for stopping 
hemorrhage, with or without hematological disorders, in massive or uncontrollable bleeding 
at multiple GI and non GI locations. Its short half-life of 2 hours requires frequent boluses or 
continuous infusion to achieve hemostasis, and it can induce definite control of bleeding or 
be a bridge until a causal therapy can be provided. It has been mainly used in cirrhotic 
patients with acquired coagulation factor deficiencies, especially in variceal and non-
variceal upper GI hemorrhage related to cirrhosis or acute liver failure.48,49 Albeit 
preliminary results showed that it might have a beneficial effect for advanced cirrhotic 
patients with variceal bleeding, a randomized placebo controlled trial failed to demonstrate 
a significant benefit of rFVIIa for controlling variceal bleeding or preventing rebleeding in 
these patients.50 Thus, the use of rFVIIa should be carefully individualized in cirrhotic 
patients and it is not recommended in the routine clinical practice. 
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This drug has been proven useful in other settings as well. In a series of 11 unselected 
patients with upper GI haemorrhage, half of them related to liver disease, rFVIIa stopped 
the bleeding in 7 patients and markedly reduced it in other 2 patients.51 Other successful 
indications relating severe GI bleeding have been refractory bleeding after endoscopic 
sphincterotomy in patients with preexisting coagulopathy,52 severe recurrent GI bleeding 
due to multiple GI angiodysplasias in a patient with vW disease,53 massive colonic 
bleeding54 or exsanguinating bleeding due to Mallory-Weiss tear.55 Of note, no 
thromboembolic events were reported in the aforementioned trials or series. However, 
secondary myocardial and cerebrovascular infarctions have been described while using 
factor VIIa.56,57 As such, it is important to stress once more that the use of this drug should 
always be carefully individualized. 
5.5 Tamoxifen 
In a recent randomized, double-blind placebo controlled trial, the efficacy of antiestrogen 
therapy (Tamoxifen) was evaluated in patients with epistaxis due to HHT.58 There was a 
significant reduction in the frequency of epistaxis in the tamoxifen-treated group, frequently 
associated to a rise in haemoglobin or a reduction in transfusion requirements. As 
previously mentioned in the case of bevacizumab, a potential therapeutic role for GI 
bleeding in HHT patients warrants further research.  
5.6 Non-selective beta-blockers  
These drugs aim to control hemorrhage by reducing gastrointestinal blood flow due to 
splanchnic vasoconstriction and reduction of cardiac output in cirrhotic patients with portal 
hypertension. Its proven benefit for secondary prophylaxis of bleeding portal hypertensive 
gastropathy in two randomized controlled trials led to the consensus recommendation that 
beta-blockers should be used for chronic bleeding once the acute episode of bleeding is 
controlled.59,60 
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